Efficacy and tolerability of escitalopram in anxiety disorders: A review;Efficacité et tolérance de l'escitalopram dans les troubles anxieux : revue de la littérature

Encephale

Volumn 34, Issue 4, 2008, Pages 400-408

  Pelissolo, A ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Anxiety disorders; Escitalopram; Generalized anxiety disorder; Obsessive compulsive disorder; Panic disorder; Social anxiety disorder

Indexed keywords

ESCITALOPRAM; PAROXETINE;

ANXIETY DISORDER; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENERALIZED ANXIETY DISORDER; HAMILTON SCALE; HUMAN; INCIDENCE; LIEBOWITZ SOCIAL ANXIETY SCALE; OBSESSIVE COMPULSIVE DISORDER; PANIC; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RELAPSE; REMISSION; RISK REDUCTION; SCORING SYSTEM; SOCIAL PHOBIA; SYMPTOMATOLOGY; TRANQUILIZING ACTIVITY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; YALE BROWN OBSESSIVE SCALE;

ANXIETY DISORDERS; CITALOPRAM; DIAGNOSIS, DIFFERENTIAL; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; PANIC DISORDER; PHOBIC DISORDERS; SEROTONIN UPTAKE INHIBITORS;

EID: 52049116874     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.encep.2008.04.004     Document Type: Article

References (33)

1. Allgulander C., Florea I., and Huusom A.K. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol 9 (2006) 495-505
2. Allgulander C., Jorgensen T., Wade A., Francois C., et al. Health-related quality of life (HRQOL) among patients with Generalised Anxiety Disorder: evaluation conducted alongside an escitalopram relapse prevention trial. Curr Med Res Opin 23 (2007) 2543-2549
3. Andlin-Sobocki P., Jönsson B., Wittchen H., et al. Cost of disorders of the brain in Europe. Eur J Neurol 12 suppl. 1 (2005) 1-27
4. Baldwin D.S., Huusom A.K., and Maehlum E. Escitalopram and paroxetine in the treatment of generalized anxiety disorder: randomised, placebo-controlled, double-blind study. Br J Psychiatry 189 (2006) 264-272
5. Baldwin D.S., Reines E.H., Guiton C., et al. Escitalopram therapy for major depression and anxiety disorders. Ann Pharmacother 41 (2007) 1583-1592
6. Beesdo K., Bittner A., Pine D.S., et al. Incidence of social anxiety disorder and the consistent risk for secondary depression in the first three decades of life. Arch Gen Psychiatry 64 (2007) 903-912
7. Bielski R.J., Bose A., and Chang C.C. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry 17 (2005) 65-69
8. Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 48 (1991) 730-738
9. Davidson J.R., Bose A., and Wang Q. Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 66 (2005) 1441-1446
10. Davidson J.R., Bose A., Korotzer A., et al. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety 19 (2004) 234-240
11. Dhillon S., Scott L.J., and Plosker G.L. Escitalopram: a review of its use in the management of anxiety disorders. CNS Drugs 20 (2006) 763-790
12. Fehm L., Pelissolo A., Furmark T., et al. Size and burden of social phobia in Europe. Eur Neuropsychopharmacol 15 (2005) 453-462
13. Fineberg N.A., Tonnoir B., Lemming O., et al. Escitalopram prevents relapse of obsessive-compulsive disorder. Eur Neuropsychopharmacol 17 (2007) 430-439
14. Goodman W.K., Bose A., and Wang Q. Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Disord 87 (2005) 161-167
15. Haute Autorité de santé. Affections psychiatriques de longue durée : troubles anxieux graves. Paris: HAS www.has-sante.fr ; 2007.
16. Kasper S., Stein D.J., Loft H., et al. Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry 186 (2005) 222-226
17. Lader M., Stender K., Burger V., et al. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety 19 (2004) 241-248
18. Lecrubier Y, Dolberg OT, Andersen HF, et al. Qualitative changes in symptomatology as an effect of treatment with escitalopram in generalized anxiety disorder and major depressive disorder. Eur Arch Psychiatry Clin Neurosci (in press) 2007 Dec 14. [Epub ahead of print].
19. Lepine J.P., and Pelissolo A. Comorbidity and social phobia: clinical and epidemiological issues. Int Clin Psychopharmacol 11 suppl. 3 (1996) 35-41
20. Lepine J.P., and Pelissolo A. Why take social anxiety disorder seriously?. Depress Anxiety 11 (2000) 87-92
21. Lepine J.P., Gasquet I., Kovess V., et al. Prévalence et comorbidité des troubles psychiatriques dans la population générale française. Encéphale 31 (2005) 182-194
22. Montgomery S.A., Nil R., Durr-Pal N., et al. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry 66 (2005) 1270-1278
23. Pelissolo A., Andre C., Chignon J.M., et al. Épidémiologie des troubles anxieux en psychiatrie libérale : prévalences, comorbidité et retentissement (étude Delta). Encéphale 28 (2002) 510-519
24. Pelissolo A., Huron C., Fanget F., et al. Les phobies sociales en psychiatrie : caractéristiques cliniques et modalités de prise en charge (étude Phoenix). Encéphale 32 (2006) 106-112
25. Pélissolo A., and Boyer P. Retentissement de l'anxiété généralisée sur l'adaptation sociale. In: Boyer P. (Ed). L'anxiété généralisée (2005), John Libbey Eurotext, Paris 123-133
26. Rampello L., Alvano A., Raffaele R., et al. New possibilities of treatment for panic attacks in elderly patients: escitalopram versus citalopram. J Clin Psychopharmacol 26 (2006) 67-70
27. Sanchez C., Bergqvist P.B., Brennum L.T., et al. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl) 167 (2003) 353-362
28. Spadone C. Effets du escitalopram sur les symptômes anxieux dans la depression. Encéphale 28 (2002) 461-465
29. Stahl S.M., Gergel I., and Li D. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 64 (2003) 1322-1327
30. Stein D.J. Obsessive-compulsive disorder. Lancet 360 (2002) 397-405
31. Stein D.J., Andersen H.F., and Goodman W.K. Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes. Ann Clin Psychiatry 17 (2005) 71-75
32. Stein D.J., Andersen E.W., Tonnoir B., et al. Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Curr Med Res Opin 23 (2007) 701-711
33. Stein D.J., Kasper S., Andersen E.W., et al. Escitalopram in the treatment of social anxiety disorder: analysis of efficacy for different clinical subgroups and symptom dimensions. Depress Anxiety 20 (2004) 175-181